Glucotrack (Nasdaq:GCTK) today announced a slight delay in its plans to submit its long-term glucose monitor to the FDA for IDE. The company said in August that it expected a fourth-quarter investigational device exemption (IDE) submission for the long-term implantable continuous blood glucose monitor (CBGM). However, it says today that it anticipates a submission in […]
Glucotrack
The top CGM stories of 2025
Millions of people worldwide are looking for ways to manage their diabetes. That’s where the continuous glucose monitor (CGM) comes in. The CGM market is expected to experience substantial, double-digit percentage growth over the next five years, reaching nearly $29 billion by 2030. Market leaders Abbott and Dexcom continue to establish their hold on the […]
Glucotrack to submit long-term CGM implant for FDA IDE this year
Glucotrack (Nasdaq:GCTK) today announced multiple developments in the timeline for its long-term continuous blood glucose monitor (CBGM). The Rutherford, New Jersey-based company plans to file an FDA investigational device exemption (IDE) submission in the fourth quarter of this year. It also remains on track to implant the first patients in a long-term, multi-center feasibility study […]
Glucotrack first-in-human study of long-term CBGM implant meets endpoints
Glucotrack (Nasdaq:GCTK) today announced the results from the first-in-human clinical study of its long-term continuous blood glucose monitor (CBGM). Rutherford, New Jersey-based Glucotrack shared findings at the American Diabetes Association’s 85th Scientific Sessions in Chicago. (See all the biggest stories out of ADA 2025 here.) Glucotrack’s device features no on-body external component. The company designed […]
The biggest diabetes tech stories out of ADA 2025
The biggest names in diabetes tech gathered in Chicago this past weekend for the American Diabetes Association’s 85th Scientific Sessions. At last year’s edition in Orlando, type 2 diabetes dominated the conversation. This time around, type 2 remained a hot topic, alongside new players in the continuous glucose monitor (CGM) and automated insulin delivery market, […]
A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
Glucotrack (Nasdaq:GCTK) believes it can tap into a diabetes market that includes millions of people who aren’t being served completely. That’s according to the company’s Chief Scientific Officer, Mark Tapsak, who gave a presentation on the company’s long-term implantable continuous blood glucose monitor (CBGM) as part of the American Diabetes Association’s 85th Scientific Sessions’ “Innovation […]
Glucotrack to effect a reverse stock split
Glucotrack (Nasdaq:GCTK) announced that it plans to effect a 1-for-60 reverse stock split of its issued and outstanding common stock. Rutherford, New Jersey-based Glucotrack — maker of a long-term implantable continuous blood glucose monitor (CBGM) — intends for the split to go into effect when the market opens on Monday, June 16, 2025. Under the terms […]
Glucotrack can proceed with long-term glucose monitor study in Australia
Glucotrack (Nasdaq:GCTK) announced today that it received a hospital’s ethical approval to study its continuous blood glucose monitor (CBGM). The St. Vincent’s Hospital Melbourne Human Research Ethics Committee (HREC) gave the nod for a long-term clinical study. It plans to include participants with both type 1 and type 2 diabetes using the CBGM. Rutherford, New […]
Glucotrack to bring implantable CBGM to automated insulin delivery system initiative in Europe
Glucotrack (Nasdaq:GCTK) announced today that it intends to participate in a bionic pancreas initiative in Europe. FORGETDIABETES aims to develop a long-term automated insulin delivery system. This system should enable optimal glucose control without patient intervention. The initiative, funded by the European Union’s Horizon 2020 research and innovation program, offers support from basic research to […]
Glucotrack expects FDA IDE for implantable CBGM this year
Glucotrack (Nasdaq:GCTK) announced that it expects FDA investigational device exemption (IDE) for its long-term CBGM later this year. Rutherford, New Jersey-based Glucotrack develops a long-term implantable continuous blood glucose monitor (CBGM). The device features no on-body external component. The company designed it for three years of continuous, accurate blood glucose monitoring for a more convenient, […]
